Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis
Are natural killer cells involved in multiple sclerosis etiology? Evidences from NKp46/NCR1 receptor modulation in an observational study.
Chemotherapeutics in the treatment of multiple sclerosis.
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
Genzyme provides update on U.S. LEMTRADA™ filing
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.
Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.
Mitoxantrone-related acute leukemia in MS: An open or closed book?
Gpr126 is essential for peripheral nerve development and myelination in mammals.
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis
IFN-β inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis.
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
Incorporating Alcohol Pharmacotherapies Into Medical Practice
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Oracle Cladribine in Early Multiple Sclerisis (MS) (ORACLE MS)
Intas launches biosimilar version of Rituximab
Repurposing drugs for disease modification in multiple sclerosis
Autoimmune Hepatitis-like reaction developing in a patient treated with Interferon beta 1a.
Top ten research priorities for spinal cord injury: the methodology and results of a British priority setting partnership.
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.

Pages